TRLVTRLVHealthcare · Drug Manufacturers - Specialty & Generic

TRLV Stock Forecast: Trulieve Cannabis Corp. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$10
−0.50% on the day

The 7 Wall Street analysts covering Trulieve Cannabis Corp. hold a median 12-month price target of $19 — +89.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 17 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
71/ 100
Median analyst target
$19
Analysts covering
7
Revenue$271.0M−10.3% y/y
Operating income$34.8M
Net income−$406.1M
Free cash flow$32.1M
Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.8%
1M
+0.1%
YTD
+15.3%
1Y
+92.7%
From 52W high
−22.9%
From 52W low
+110.5%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Trulieve Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
71/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Issuance
87
Value
74
Volatility
69
Momentum
66
Quality
59
Revisions
36
Size
34
Growth
28

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TRLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26TRLVHigh $22Median $19Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $15Median $19High $22

The green dot is the last close — the median target sits +89.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Nov 2026Cantor FitzgeraldReiteratesOverweight$15
23 Oct 2026Cantor FitzgeraldReiteratesOverweight—
23 Oct 2026Cantor FitzgeraldReiteratesOverweight$15
7 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
7 Aug 2026Cantor FitzgeraldReiteratesOverweight—
20 July 2026Cantor FitzgeraldInitiatesOverweight$15
20 July 2026Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TRLV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TRLV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Trulieve Cannabis Corp. returned +92.7% against +12.2% for the S&P 500, dividends included.

TRLV vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26TRLVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TRLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Trulieve Cannabis Corp. (TRLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.8×

Cheaper than 96% of US stocks

Price / sales
1.6×

Cheaper than 54% of US stocks

Price / book
2.6×

Cheaper than 32% of US stocks

EV / EBITDA
7.6×

Cheaper than 44% of US stocks

Growth & margins
Revenue growth (YoY)
−20.1%

Higher than 11% of US stocks

Earnings growth (YoY)
−10.3%

Higher than 27% of US stocks

Gross margin
59.9%

Higher than 73% of US stocks

Operating margin
12.2%

Higher than 70% of US stocks

Net margin
−41.2%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−45.6%

Higher than 22% of US stocks

Return on assets
3.3%

Higher than 66% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Trulieve Cannabis Corp. (TRLV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Trulieve Cannabis Corp. has a market value of $1.7B and an enterprise value of $2.2B.

  • Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter shrank 20.1% year on year.

  • Net income over the same four quarters: −$476.2M, a −41.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.45.

  • Free cash flow in the twelve months to 30 June 2026: $186.2M, after $50.2M of capital spending.

  • Shares outstanding: 192.4M.

  • Trailing P/E: −16.8×; forward P/E: 34.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Trulieve Cannabis Corp. employs 5,000 people — $228K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

TRLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TRLVTrulieve Cannabis Corp.$1.7B71
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82
ETONEton Pharmaceuticals, Inc.$1.8B99
PRGOPerrigo Co. Plc$2.2B90
RGCRegencell Bioscience Holdings Ltd.$2.3B22
PBHPrestige Consumer Healthcare, Inc.$2.3B57
ANIPANI Pharmaceuticals, Inc.$1.6B98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Trulieve Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRLV news & analysis

Trulieve to Open Medical Cannabis Dispensary in Tampa, Florida

PRNewsWire · 16 Nov 2026positive

Trulieve announced the opening of a medical cannabis dispensary in Tampa, Florida. The new Hillsborough County location will hold a grand opening celebration on Friday, November 20.

Why it matters — The announcement adds a new Trulieve dispensary location in Florida for investors tracking the company’s operations.

Trulieve Announces Preliminary Addition to the Russell 2000® and 3000® Indices

PRNewsWire · 16 Nov 2026positive

Trulieve announced it is set to join the Russell 2000® and Russell 3000® Indices as part of the semi-annual reconstitution, according to FTSE Russell’s preliminary list published November 13, 2026.

Why it matters — The preliminary index addition is a corporate development relevant to investors following Trulieve’s index inclusion.

Trulieve Announces November 2026 Event Participation

PRNewsWire · 11 Nov 2026neutral

Trulieve announced planned participation in events during November 2026.

Why it matters — The announcement provides TRLV watchers with information about the company's planned event activity.

Trulieve Expands Medical Cannabis Access through Riverside Pharmacy in Gainesville, Georgia

PRNewsWire · 10 Nov 2026positive

Trulieve announced that its medical cannabis products are available to qualified patients at Riverside Pharmacy in Gainesville, Georgia. A Trulieve-branded kiosk provides product access, education, and personalized guidance.

Why it matters — The announcement adds a pharmacy location where qualified patients can access Trulieve products in Georgia.

Marijuana Stocks In 2027: New Risks And Opportunities For Investors

MarijuanaStocks · 9 Nov 2026neutral

The provided text includes only the headline “Marijuana Stocks In 2027: New Risks And Opportunities For Investors” and the source, MarijuanaStocks; it does not describe any specific events or details.

Why it matters — The headline indicates a broad discussion of future risks and opportunities in marijuana stocks, but the supplied text offers no TRLV-specific information.

FAQ

Frequently asked questions about TRLV stock

What is the TRLV stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Trulieve Cannabis Corp. have a median 12-month price target of $19, with estimates ranging from $15 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRLV stock a buy right now?

Of the 7 analysts covering Trulieve Cannabis Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trulieve Cannabis Corp. 71 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRLV?

As at 17 Nov 2026, Trulieve Cannabis Corp. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will TRLV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +89.6% from the last close, and Ticker Nerd's factor model ranks Trulieve Cannabis Corp. 71 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRLV stock forecast for 2030?

No analyst covering Trulieve Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $22 over the next 12 months.

How has TRLV stock performed over the past year?

Trulieve Cannabis Corp. returned +92.7% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Trulieve Cannabis Corp. do?

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures, and retails cannabis products across the United States.

What is the latest news on TRLV?

The most recent item we track (PRNewsWire, 16 Nov 2026): "Trulieve to Open Medical Cannabis Dispensary in Tampa, Florida". Trulieve announced the opening of a medical cannabis dispensary in Tampa, Florida. The new Hillsborough County location will hold a grand opening celebration on Friday, November 20.

Company

About Trulieve Cannabis Corp.

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures, and retails cannabis products across the United States. The company serves medical patients and adult-use consumers where permitted, using a network of branded dispensaries and home delivery services to distribute its products. Its portfolio includes flowers, edibles, vapes, concentrates, tinctures, topicals, and accessories sold under brands such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One. Trulieve also operates cultivation and processing facilities that support product quality, supply consistency, and in-house production. The company plays a significant role in the U.S. cannabis market, with a strong emphasis on regulated retail, product development, and state-compliant operations.

CEO Ms. Kimberly Rivers J.D. · 5,000 employees · United States · https://www.trulieve.com